Thermo Fisher Scientific Completes Two Major Acquisitions: Sanofi's Ridgefield Facility and Solventum's Purification & Filtration Business

Thermo Fisher Scientific recently announced that it has completed the acquisition of Sanofi's advanced aseptic filling and packaging facility located in Ridgefield, New Jersey. This move marks a further expansion of the strategic partnership between the two parties to support the increase in U.S. drug manufacturing capacity. The terms of the transaction were not disclosed. After the completion of the acquisition, the Ridgefield facility will be integrated into Thermo Fisher's Pharma Services business within its Laboratory Products and Biopharma Services segment.

According to the agreement, Thermo Fisher will continue to produce a series of therapeutic products for Sanofi at its Ridgefield facility, while further expanding the plant's capacity to meet the growing demand for U.S.-based production from pharmaceutical and biotechnology customers.

Thermo Fisher Scientific Chairman, President and CEO Marc N. Casper commented, "We are very pleased to bring Sanofi's Ridgefield facility into the Thermo Fisher network and welcome more than 200 experienced colleagues to our team. This world-class facility and talent will strengthen our U.S. manufacturing capabilities, better support pharmaceutical and biotechnology customers, and lay a solid foundation for future expansion."

Thermo Fisher currently operates the world's leading aseptic filling production network, and the Ridgefield facility will complement its two existing sites in Greenville, North Carolina, and Plainville, Massachusetts. These sites are an integral part of the company’s Accelerator™ Drug Development 360° CDMO and CRO solutions, committed to transforming the pharmaceutical value chain for emerging biotech and biopharmaceutical companies and accelerating the delivery of life-changing medicines to patients.

Thermo Fisher Scientific Inc. recently announced the completion of its acquisition of Solventum's purification and filtration business for approximately $4 billion in cash. Following the acquisition, this business will become part of Thermo Fisher’s Filtration and Separation Business, under the Life Sciences Solutions Segment.

This acquisition covers Solventum's purification and filtration businesses, which include bioprocessing filtration, medical and industrial filtration, and membrane materials. Through this transaction, Thermo Fisher Scientific will further strengthen its comprehensive solutions in the bioproduction field, enhancing the quality and efficiency of upstream and downstream production processes with advanced filtration technologies. Meanwhile, its robust industrial filtration and membrane technologies will expand Thermo Fisher’s application markets in ultrapure water-related industries, including batteries, semiconductors, and medical device manufacturing. The business is expected to generate approximately $750 million in revenue for the full year of 2025.

Marc N. Casper, Chairman, President and Chief Executive Officer of Thermo Fisher Scientific, said: "We warmly welcome the colleagues from the filtration and separation business to join the Thermo Fisher family. The innovative filtration technology brought by this acquisition is highly complementary to our existing bioprocessing portfolio, enabling us to better meet the end-to-end needs of pharmaceutical and biotech customers in a fast-growing market. At the same time, this business will also help us expand into adjacent markets with growth potential."

As part of Thermo Fisher, the Filtration and Separation business is expected to achieve mid- to high-single-digit organic growth. The application of the PPI Business System is anticipated to drive significant margin improvement and synergies. In the first year post-acquisition, the transaction is expected to have a $0.06 dilutive impact on adjusted earnings per share (EPS). Thermo Fisher anticipates strong day-one cost synergies as Solventum’s existing allocated costs are replaced by Thermo Fisher’s lower long-term cost structure, offset by one-time business start-up costs and financing expenses. By the fifth year after closing, Thermo Fisher expects revenue and cost synergies to contribute approximately $125 million in adjusted operating income. The projected long-term business growth, margin expansion opportunities, and synergy realization make the financial returns of the deal highly compelling, with an expected internal rate of return in the double digits.